Background: Infantile hemangiomas have a dramatic response to propranolol, a nonselective beta-blocker. However, this treatment is not risk-free and many patients are excluded because of respiratory comorbidities. Atenolol is a cardioselective beta-blocker that may have fewer adverse events.
Objective: We sought to evaluate the effectiveness of atenolol against propranolol in a noninferiority trial.
Methods: In all, 23 patients met the inclusion criteria and were randomized to receive either atenolol or propranolol. Thirteen patients were treated with atenolol and 10 with propranolol. Follow-up was made at baseline, 2 weeks, 4 weeks, and then monthly for 6 months.
Results: Patients treated with atenolol had a complete response of 53.8% and 60% with propranolol, respectively. These results were nonsignificant (P = .68). Relevant adverse events were not reported.
Limitations: The reduced number of patients could have influenced our results.
Conclusion: Atenolol appears to be as effective as propranolol. We did not find significant differences between these results or any adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2014.01.905 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Looking at the albumin-drug binding via partitioning in aqueous two-phase system.
Biochem Biophys Res Commun
January 2025
Cleveland Diagnostics, 3615 Superior Ave., Cleveland, OH, 44114, USA. Electronic address:
The partition coefficient of human serum albumin (HSA) was analyzed in the PEG600-Dex70, 0.15 M NaCl/KCl in 0.01 M Na/K phosphate buffer, pH 7.
View Article and Find Full Text PDFPharmacogenetic and microRNA mechanisms of beta blocker use on bone.
J Bone Miner Res
December 2024
Division of Endocrinology and Kogod Center on Aging, Mayo Clinic, Rochester, MN.
Motivated by studies showing an association between beta blocker (BB) use and positive bone outcomes, a pilot randomized control trial (RCT) was performed at the Mayo Clinic which randomized postmenopausal women to placebo, propranolol (40 or 80 mg twice daily), atenolol (50 mg/day), or nebivolol (5 mg/day) to determine changes in bone turnover markers (BTMs) and in bone mineral density (BMD) over 20 weeks. Pharmacogenetic effects and microRNA-mediated mechanisms involving beta adrenergic receptor and related genes have previously been found. We sought to validate these effects and discover new candidates in an ancillary study to the pilot clinical trial.
View Article and Find Full Text PDFStress and obesity signaling converge on CREB phosphorylation to promote pancreatic cancer.
Mol Cancer Res
December 2024
University of California, Los Angeles, Los Angeles, CA, United States.
One of the deadliest types of cancer is pancreatic ductal adenocarcinoma (PDAC). Chronic stress and obesity are recognized as risk factors for PDAC. We hypothesized that the combination of stress and obesity strongly promotes pancreatic cancer development and growth.
View Article and Find Full Text PDFImpact of Beta-Blocker Therapy on Pregnant Women With Long QT Syndrome: A Systematic Review.
Cureus
October 2024
Obstetrics and Gynaecology, An-Najah National University, Nablus, PSE.
Long QT syndrome (LQTS) presents significant challenges for pregnant women due to the elevated risk of arrhythmic events. Beta-blocker therapy is a cornerstone of treatment in managing LQTS, but its use during pregnancy introduces potential fetal risks. This systematic review synthesizes the evidence on the efficacy and safety of beta-blocker therapy in pregnant women with LQTS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!